MedTrace Logo

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer

NCT06492941 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2024-07-09

No results posted yet for this study

Summary

This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.

Conditions

  • Advanced Pancreatic Cancer

Interventions

DRUG

Docetaxel for Injection (Albumin bound)

Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.

DRUG

Placebo

Placebo was human blood albumin without the active ingredient docetaxel

DRUG

Best supportive care

Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2026-04-14
Completion
2026-11-21

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492941 on ClinicalTrials.gov